Shares of Laboratory Corp. of America Holdings (NYSE:LH) gapped up before the market opened on Thursday . The stock had previously closed at $140.13, but opened at $140.15. Laboratory Corp. of America Holdings shares last traded at $140.81, with a volume of 139,330 shares changing hands.

Several equities analysts have recently commented on the stock. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $143.00 price target (up previously from $135.00) on shares of Laboratory Corp. of America Holdings in a research report on Thursday, June 9th. Barclays PLC increased their price target on shares of Laboratory Corp. of America Holdings from $152.00 to $155.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 26th. Canaccord Genuity set a $155.00 price target on shares of Laboratory Corp. of America Holdings and gave the stock a “buy” rating in a research report on Thursday, July 28th. Jefferies Group increased their price target on shares of Laboratory Corp. of America Holdings from $121.00 to $131.00 and gave the stock a “hold” rating in a research report on Tuesday, April 26th. Finally, KeyCorp reaffirmed a “buy” rating and set a $143.00 price target on shares of Laboratory Corp. of America Holdings in a research report on Sunday, May 22nd. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $138.15.

The company’s 50-day moving average price is $135.83 and its 200-day moving average price is $122.85. The company has a market cap of $14.42 billion and a price-to-earnings ratio of 23.41.

Laboratory Corp. of America Holdings (NYSE:LH) last posted its quarterly earnings data on Wednesday, July 27th. The company reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.33 billion. During the same quarter in the previous year, the firm posted $2.09 EPS. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. Equities research analysts expect that Laboratory Corp. of America Holdings will post $8.82 EPS for the current fiscal year.

In related news, Director Robert E. Mittelstaedt, Jr. sold 992 shares of the company’s stock in a transaction dated Thursday, August 4th. The shares were sold at an average price of $140.15, for a total value of $139,028.80. Following the sale, the director now owns 12,340 shares of the company’s stock, valued at $1,729,451. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Lisa J. Uthgenannt sold 1,177 shares of the company’s stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $140.00, for a total transaction of $164,780.00. Following the completion of the sale, the insider now directly owns 3,660 shares in the company, valued at approximately $512,400. The disclosure for this sale can be found here.

A number of institutional investors have recently added to or reduced their stakes in the stock. KBC Group NV raised its position in Laboratory Corp. of America Holdings by 14.9% in the fourth quarter. KBC Group NV now owns 11,077 shares of the company’s stock worth $1,370,000 after buying an additional 1,437 shares during the period. State of Tennessee Treasury Department raised its position in Laboratory Corp. of America Holdings by 2,084.8% in the fourth quarter. State of Tennessee Treasury Department now owns 334,282 shares of the company’s stock worth $41,331,000 after buying an additional 318,982 shares during the period. Dimensional Fund Advisors LP raised its position in Laboratory Corp. of America Holdings by 10.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 450,759 shares of the company’s stock worth $55,733,000 after buying an additional 42,589 shares during the period. BNP Paribas Arbitrage SA raised its position in Laboratory Corp. of America Holdings by 229.8% in the fourth quarter. BNP Paribas Arbitrage SA now owns 33,888 shares of the company’s stock worth $4,190,000 after buying an additional 23,612 shares during the period. Finally, Jennison Associates LLC raised its position in Laboratory Corp. of America Holdings by 57.6% in the fourth quarter. Jennison Associates LLC now owns 1,434,775 shares of the company’s stock worth $177,396,000 after buying an additional 524,488 shares during the period.

Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.